Floatz logo

VEMURAFENIB

Thyroid Carcinoma, Anaplastic

Cancer Research UKSmall moleculePhase 2/3Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Thyroid Carcinoma, Anaplastic cohort.

Asset / SponsorPhaseRating
gsk1120212
Cancer Research UK
Phase 2/3B
Cobimetinib
Cancer Research UK
Phase 2/3B
Dabrafenib
Cancer Research UK
Phase 2/3B
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2CCC
Nivolumab
M.D. Anderson Cancer Center
Phase 2CCC

View all 24 →

Same molecule, other indications

VEMURAFENIB is also rated in:

melanomaDormant
BB
Indicative ·
66 / 100
View asset →
metastatic melanomaDormant
B
Indicative ·
63 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →